GlobeNewswire Clinical StudiesOriginal article
IL-23 Inhibitors Gain Physician Preference for IBD Across Europe, Yet Actual Use Continues to Lag, According to Spherix Global Insights
IL-23 InhibitorsPositive
AI Analysis
Summary
Spherix Global Insights research reveals growing physician preference for IL-23 inhibitors in treating inflammatory bowel disease across EU4+UK, though actual clinical use lags behind physician preference, indicating an undertreated patient population.
Importance:3/10
Sentiment:
0.30
IBDIL-23 inhibitorsPhysician preferenceReal-world useMarket researchEuropeCrohn's diseaseUlcerative colitis
Read the original article
Published by GlobeNewswire Clinical Studies on August 13, 2026 5:45 PM